Congressman Carter "THE DEA IS THE EPITOME OF INEPTITUDE" MMJ International Holdings, MMJ BioPharma Labs, and MMJ BioPharma Cultivation the premier medical cannabis research companies announced that it has completed the FDA required manufacturing of its proprietary THC and CBD marijuana soft gelatin capsule. MMJ International Holdings has several filings with the FDA in Multiple Sclerosis and Huntington's disease and is developing a non-synthetic oral drug product from the marijuana plant extracts. MMJ will be utilizing its new product for its clinical trials once FDA approved.

1. H O W M M J B I O P H A R M A
C U L T I V A T I O N M A K E S
D E A G R O W N I N G
M A R I J U A N A
I N N O V A T I V E A N D V A N C E S
DUA NE BO ISE PR E SE NTS
DEA ”EPITOME OF INEPTITUDE”

2. MMJ BIOPHARMA CULTIVATION
A DEA API Bulk Manufacturer
applicant to grow marijuana has
recently deployed an innovative
precision cultivation equipment. With
this innovative cultivation
technology MMJ BioPharma
Cultivation will be able to reproduce
multiple, quality strain specific
cannabis plants, to meet the DEA’s
definition of chemical reproducibility
of quality marijuana.

3. The DEA has received multiple comments that expressed concerns
about the quality of marijuana that will be produced under the
DEA's new rule.
Issue: Some commenters stated that the current quality of
marijuana produced for Federal research is of poor quality.
Response: The purpose of this rule is to increase the number and
variety of marijuana growers in order to diversify the supply
available to researchers. As proposed in the NPRM and finalized in
the rule, one of the DEA's selection criteria for marijuana grower
applicants is the‘‘applicant's ability to consistently produce and
supply cannabis of a high quality and defined chemical
composition.''
M M J B I O P H A R M A
C U LT I VAT I O N Q UA L I T Y O F
. M A R I J UA N A

4. New research now underway at MMJ
BioPharma Cultivation will ensure that schedule
1 DEA approved researchers will soon be able to
obtain their cannabis products for clinical trials.
Duane Boise, president of MMJ stated "the
growing equipment has sophisticated
monitoring devices that collects an
unprecedented amount of data analytics.
Having the ability to collect this data about the
growing process of the plant will allow MMJ
analyst the ability to dial in the specific formula
for the same scientific outcomes in clinical
trials".
M M J B I O P H A R M A C U LT I VAT I O N S C I E N T I F I C
B R E A K T H R O U G H S

5. Dr. Elio Mariani CEO and chief
science officer mentioned " this is a
bold financial move on behalf of the
company because we are still
awaiting the DEA to issue MMJ's
registration to grow pharmaceutical
grade marijuana. We expect the
company issue with the DEA will be
resolved soon."
MMJ MAKES BOLD MOVE

6. MMJ has filed suit against the DEA for
dragging their feet on the matter of
not issuing the registration in a timely
manner. Currently, MMJ BioPharma is
nearing completion of its state-of-the-
art, marijuana center of excellence,"
stated the firm in a press release.
MMJ MARIJUANA CENTER OF EXCELLENCE